333987-99-8

Basic information

• Product Name: Piperidine, 1-acetyl-4-[[4-[(1-methylethyl)sulfonyl]phenyl]methyl]-
• CAS NO: 333987-99-8
• Molecular Formula: C17H25NO3S
• Molecular Weight: 323.456
• Mol File: 333987-99-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Piperidine, 1-acetyl-4-[[4-[(1-methylethyl)sulfonyl]phenyl]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidine, 1-acetyl-4-[[4-[(1-methylethyl)sulfonyl]phenyl]methyl]-(333987-99-8)
• EPA Substance Registry System: Piperidine, 1-acetyl-4-[[4-[(1-methylethyl)sulfonyl]phenyl]methyl]-(333987-99-8)

Safety Data

• Hazardous Substances Data: 333987-99-8(Hazardous Substances Data)

Upstream product

• 333795-03-2 4-[(1-acetyl-4-piperidinyl)methyl]benzenesulfonyl chloride 
• 101997-42-6 1-(4-benzylpiperidin-1-yl)ethan-1-one 
• 31252-42-3 4-benzylpyperidine 
• 333987-97-6 4-[(1-acetylpiperidin-4-yl)methyl]benzenethiol 
• 333987-98-7 1-acetyl-4-[4-(isopropylsulfanyl)benzyl]piperidine 

Relevant articles and documents

CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives

Replacement of the 5-oxopyrrolidin-3-yl fragment in the previously reported lead structure with a 1-acetylpiperidin-4-yl group led to the discovery of a novel series of potent CCR5 antagonists. Introduction of small hydrophobic substituents on the central phenyl ring increased the binding affinity, providing low to sub-nanomolar CCR5 antagonists. The selected compound 11f showed excellent antiviral activity against CCR5-using HIV-1 replication in human peripheral blood mononuclear cells (EC50 = 0.59 nM) and an acceptable pharmacokinetic profile in dogs.

Cyclic amine compounds as CCR5 antagonists

A compound of formula (I) (wherein R1is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1and R2may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+—R5.Y?(R5is a hydrocarbon group; Y?is a counter anion); R3is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1is a bond, CO or SO2; G2is CO, SO2, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3aliphatic hydrocarbon which may be substituted; provided that J is methine when G2is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G1is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).